Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Jul 2:13:324.
doi: 10.1186/1471-2407-13-324.

Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid

Affiliations
Comparative Study

Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid

Arnaud Scherpereel et al. BMC Cancer. .

Abstract

Background: Malignant pleural effusions (MPE) are a common and fatal complication in cancers including lung or breast cancers, or malignant pleural mesothelioma (MPM). MPE animal models and immunotherapy trials in MPM patients previously suggested defects of the cellular immunity in MPE. However only few observational studies of the immune response were done in MPM patients, using questionable control groups (transudate…).

Methods: We compared T cell populations evaluated by flow cytometry from blood and pleural effusion of untreated patients with MPM (n = 58), pleural metastasis of adenocarcinoma (n = 30) or with benign pleural lesions associated with asbestos exposure (n = 23). Blood and pleural fluid were also obtained from healthy subjects, providing normal values for T cell populations.

Results: Blood CD4+ or CD8+ T cells percentages were similar in all groups of patients or healthy subjects. Whereas pleural fluid from healthy controls contained mainly CD8+ T cells, benign or malignant pleural effusions included mainly CD4+ T cells. Effector memory T cells were the main T cell subpopulation in pleural fluid from healthy subjects. In contrast, there was a striking and selective recruitment of central memory CD4+ T cells in MPE, but not of effector cells CD8+ T cells or NK cells in the pleural fluid as one would expect in order to obtain an efficient immune response.

Conclusions: Comparing for the first time MPE to pleural fluid from healthy subjects, we found a local defect in recruiting effector CD8+ T cells, which may be involved in the escape of tumor cells from immune response. Further studies are needed to characterize which subtypes of effector CD8+ T cells are involved, opening prospects for cell therapy in MPE and MPM.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of T cell populations in blood and pleural fluid of healthy subjects. Distribution of CD4+ T cells (A), and CD8+ (F) T cells, as well as subtypes of naive (panels B and G), central memory - TCM (panels C and H), effector memory - TEM (panels D and I) and terminaly diferentiated - TTD (panels E and K) in blood and pleural fluid. Numbers above each plot represent median values with interquartile range in squares.
Figure 2
Figure 2
Distribution of populations in pleural fluid of patients vs. healthy subjects. Distribution of CD4+ (A) or CD8+ (B) T cell subsets, as well as the CD4+/CD8+ T (C) cell ratio and NK cells )D) in the pleural fluid of different groups of patients (pleural metastasis of adenocarcinoma = METS group), patients with benign pleural lesions associated with asbestos exposure = BPLAE group), and patients with malignant pleural mesothelioma = MPM group) vs. healthy subjects. Horizontal line in boxes represent median values, box limits represent 25th (Q1) and 75th (Q3) centiles and whiskers minimal and maximal values.
Figure 3
Figure 3
Distribution of T cell subpopulations in pleural fluid of patients vs. healthy subjects. Distribution of naive, central memory - TCM, effector memory - TEM, and terminally differentiated - TTD T cells among CD4+ and CD8+ T cell populations. Results are expressed as percentage of the total number of CD4+ and CD8+ T cells respectively.

Similar articles

Cited by

References

    1. Sahn S. In: Pleural disease. Bouros D, editor. London: Informa Healthcare; 2004. Malignant pleural effusions; pp. 411–438.
    1. Scherpereel A. et al.Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–495. doi: 10.1183/09031936.00063109. - DOI - PubMed
    1. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma – possible immunological mechanism. Lung Cancer. 2001;32(2):197–201. doi: 10.1016/S0169-5002(00)00217-8. - DOI - PubMed
    1. Astoul P. et al.Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 1998;83(10):2099–2104. doi: 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3. - DOI - PubMed
    1. Boutin C. et al.Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994;74(9):2460–2467. doi: 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N. - DOI - PubMed

Publication types

MeSH terms